Last reviewed · How we verify

Postoperative pain management with metamizole

Medical University of Silesia · FDA-approved active Small molecule

Metamizole inhibits prostaglandin synthesis by blocking cyclooxygenase enzymes, reducing pain and fever through central and peripheral analgesic and antipyretic effects.

Metamizole inhibits prostaglandin synthesis by blocking cyclooxygenase enzymes, reducing pain and fever through central and peripheral analgesic and antipyretic effects. Used for Postoperative pain management.

At a glance

Generic namePostoperative pain management with metamizole
SponsorMedical University of Silesia
Drug classNon-selective NSAID (nonsteroidal anti-inflammatory drug)
TargetCyclooxygenase (COX-1 and COX-2)
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Metamizole (dipyrone) is a non-selective inhibitor of cyclooxygenase (COX) enzymes, which decreases prostaglandin production in both the central nervous system and peripheral tissues. This dual action reduces pain signal transmission and lowers the hypothalamic pain set point, making it effective for acute postoperative pain management. The drug also has mild anti-inflammatory properties that contribute to its analgesic efficacy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results